Clear Search

Showing 2 results for “BILAG” published 2022.

May 2022

Efficacy and Safety of Obinutuzumab in Systemic Lupus Erythematosus Patients with Secondary Non-response to Rituximab

Rheumatology 2022;00:1–5 DOI.org/10.1093/rheumatology/keac150

Arnold, et al. present the first case series reporting the efficacy and safety of obinutuzumab in patients with treatment refractory SLE. The results indicate that, for this group of patients with limited treatment approaches, obinutuzumab could be a potential option.

more…

March 2022

Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index

Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keab883

Easy-BILAG is a high-accuracy, time-efficient tool for recording BILAG-2004 disease activity in systemic lupus erythematosus (SLE).

Disease activity measurements in SLE are necessary for optimal patient care, treat-to-target approaches and clinical guidelines. However, administrative burden and potential frequency of errors with the current comprehensive disease activity instrument (BILAG-2004) limits its use in routine practice.

more…